Signalling Pathways in Bronchial Neuroendocrine Tumor Disease and Its Translation to Innovative Targets: The New Kid on the Block

#1003

Introduction: Bronchial neuroendocrine neoplasias comprise a wide spectrum of well-differentiated tumors (typical/atypical carcinoids) to undifferentiated carcinomas such as small (SCLC) and large cell (LC) neuroendocrine carcinomas with a fatal prognosis. Therapeutic options are unsatisfactory.

Aim(s): To further elucidate the signalling pathways and crosstalks in order to define potential druggable targets in different neuroendocrine tumor cell lines of the lung. In addition, we define the role of FoxM1 and survivin in the subset of SCLC.

Materials and methods: A wide panel of neuroendocrine tumor cell lines, namely NCI-H727 (typical carcinoid), NCI-H720 (atypical carcinoid), NCI-H810 (LC lung carcinoma), NCI-H2171 (SCLC) and A549 (NSCLC; control) are characterized by FACS analysis and western blot analysis for typical neuroendocrine features. Furthermore, western blot analysis is performed to find differences in crucial signalling axes (PI3K-mTOR; MDM2-p53-pRb; MAPK). One-hundred and forty patients with SCLC (257 specimens) from a single institution (Zentralklinik Bad Berka GmbH) are stained immunohistochemically for FoxM1 and survivin expression.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Lewens F

Authors: Lewens F, Freitag H, Briest F, Heilmann M, Schneider C,

Keywords: bronchial, NETs, PI3K, FoxM1, survivin, cell lines, SCLC,